Answers are grounded in this paper and cite their sources.
Contemporary natural killer (NK) cell-based cancer therapies include adoptive transfer of autologous and allogenic NK cells, chimeric antigen receptor-engineered NK (CAR-NK) cell therapy and the use of bispecific or trispecific NK cell engagers.1 These emerging technologies capitalise on the innate cytotoxicity of NK cells and their ability to recognise malignant cells in an antigen/major histocompatibility complex independent manner, offering reduced risk of graft-versus-host disease and cytokine release syndrome seen in T cell-based therapies.2 However, clinical efficiency remains limited by poor NK cell persistence in vivo and impaired functionality within the tumour microenvironment. Overcoming these barriers is a critical challenge in the field.3
No takes yet. Share an insight, caveat, or question.
Luddy et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: